丝裂霉素C在顽固性食管狭窄中的应用进展

The application of mitomycin-C in refractory esophageal strictures

食管良性狭窄是临床常见疾病之一,其首选治疗方案为内镜下扩张。对于扩张效果不佳的顽固性食管狭窄其治疗干预措施有限。丝裂霉素C(Mitomycin-C,MMC)是一种兼具抗肿瘤和抑制增殖双重作用的抗生素,作为抗增殖抗生素最先运用于眼科领域,局部辅助应用MMC可成为顽固性食管狭窄可行安全的改善疗法。文中旨在对近年腐蚀性食管狭窄、内镜黏膜下剥离术后食管狭窄、食管闭锁修复术后食管狭窄、放疗后食管狭窄以及局部应用MMC改善狭窄现状作一综述。

Gastrointestinal benign stricture is one of common diseases in clinics,endoscopic dilation is its preferred treatment.However,for the dilation ineffective refractory strictures,it represents a difficult management problem given the limited therapeutic interventions available. Mitomycin-C is an antibiotic which has the dual role of anti-tumor and anti-proliferation. As an anti-proliferative drug,it was first applied in the field of ophthalmology. Local auxiliary application of MMC can be a feasible and safe measurement to improve the efficacy of refractory esophageal strictures. The aim of this study is to perform a systematic review which employs mitomycin C in the treatment of refractory esophageal strictures caused by corrosion,endoscopic submucosal dissection,esophageal atresia reparation and radiotherapy.